Ozempic is changing how we spend money and time, plus what we eat

⭐ Join our community and access the best we offer!

illuminem summarises for you the essential news of the day. Read the full piece on The Washington Post or enjoy below:

🗞️ Driving the news: GLP-1 weight-loss drugs such as Ozempic, Wegovy, Mounjaro and Zepbound are reshaping America’s consumer economy
• With 12.4% of U.S. adults now taking them—double the share from last year—demand patterns across food, fitness, fashion and travel are shifting rapidly as users experience appetite suppression, body changes, and lifestyle adjustments

🔭 The context: Users are buying fewer snacks and dining out less while increasing spending on supplements, fresh produce, activewear and fitness services
• Companies across sectors — from grocery chains and fast-food brands to gyms, hotels and beauty retailers — are restructuring product lines and marketing strategies to meet a new consumer mindset driven by reduced “food noise,” greater body confidence, and concern about muscle loss
• With obesity rates dipping slightly (from 40% to 37% since 2022), investors see GLP-1s as a long-term force reshaping household behavior

🌍 Why it matters for the planet: Changes in consumption could ripple through environmental footprints
• Declining demand for ultra-processed foods and alcohol may reduce emissions-intensive production, while higher purchases of fresh produce and active-lifestyle goods could shift agricultural and retail supply chains toward healthier, lower-impact products
• But surging demand for supplements, disposable packaging, and frequent travel could increase resource use
• How companies adapt — toward sustainable manufacturing, plant-forward foods, and low-carbon wellness tourism — will shape the net climate impact

⏭️ What’s next: Firms are rolling out “GLP-1-friendly” menus, protein-forward frozen meals, redesigned gyms, targeted travel packages, and expanded in-club medical clinics prescribing the drugs
• Analysts expect more businesses to tailor offerings to users coming off the medication and seeking long-term weight stability
• But access remains unequal: annual costs can reach $6,000, with many Americans battling insurers despite new federal steps to lower prices for Medicaid and Medicare patients

💬 One quote: “It’s revolutionary. GLP-1s will play a huge role in society.” — Diana Melencio, XRC Ventures

📈 One stat: Nonalcoholic wine and beer purchases among GLP-1 users jumped 1,158% and 935%, respectively, in one year.

See on illuminem's Data Hub™ the sustainability performance — carbon credit purchases, total emissions, and climate targets of thousands of companies

Click for more news covering the latest on sustainable lifestyle